Search Results

<< Back to podcast list Strategic Partner(s) Dr. Yamina Berchiche About this episode GPCRs have played a central role in my scientific career ever since I took Dr. Michel Bouvier’s class as an undergraduate student at the University of Montreal in early 2000. During the past 2 decades, my research mainly focused on chemokine receptor structure/function relationships. For the purposes of this presentation, I will walk you through my various career experiences and include the skills I learned during each experience, which ultimately led me to found Dr. GPCR. Last, I will give an overview of the various programs we established at Dr. GPCR, present our team as well as provide you with a sneak peek of our future podcast guests and more. I gave a talk on October 12th at the 3rd ERNEST meeting about the Dr.GPCR Ecosystem . I want to say thank you to the ERNEST meeting organizers for the invitation with special thanks to Dr. Martha Summer and Dr. Alexander Hauser , and Luise Wagner . For more information about the ERNEST network, visit https://ernest-gpcr.eu/ . Dr. Yamina Berchiche on the web D r. GPCR Ecosystem Member Website LinkedIn Publications Twitter Facebook Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Khaled Abdelrahman About Dr. Khaled Abdelrahman Dr. Khaled Abdelrahman graduated in 2006 with a BSc in Pharmaceutical Sciences from Alexandria University (Egypt) followed by MSc in Pharmacology in the same university that was conferred in 2009. He joined the laboratory of Dr. William Cole at the University of Calgary in 2010 for his Ph.D. where he studied the molecular basis underlying altered cerebrovascular function and blood flow in type 2 diabetes. In 2015, He joined Dr. Stephen Ferguson’s laboratory in the Departments of Cellular & Molecular Medicine and Neuroscience at the University of Ottawa as a Postdoctoral Fellow to explore novel G protein-coupled receptor (GPCR) candidates that can be targeted pharmacologically to slow neurodegeneration. He has been also studying what aspects of GPCR signaling are regulated in a sex-selective manner and how this can influence drug discovery in the area of neurodegenerative diseases. He is also a Registered Pharmacist in Canada and held two of the most prestigious Clinician Postdoctoral Fellowships offered by Alberta Innovates and Canadian Institutes of Health Research. He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics. Dr. Khaled Abdelrahman on the web Twitter PubMed Google Scholar Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Home → Flash News → master gpcr pharmacologic models before its too late Published on July 11, 2025 Category GPCR Weekly News Most GPCR teams aren’t failing because of bad science. They’re stalling because of slow decisions, misapplied models, and buried priorities. This week’s GPCR Weekly News helps you fix that. Terry’s Corner breaks down the 4 pharmacologic models that separate forecasting from guessing. Dr. Sokhom S. Pin shares how he built high-output, low-burnout teams—and earned his PhD while working full time. Yamina’s Corner exposes the silent drift killing GPCR programs (and how to reverse it). 💡Plus: New tools from Celtarys Research . Biotech strategy moves from Catalio Capital Management . And your voice in our survey. If your competitors are already applying these insights… can you afford to skip this week’s update? ✳️ Read the Weekly News → https://www.ecosystem.drgpcr.com/post/crush-data-confusion-conquer-gpcr-drug-discovery?utm_content=bufferd9b30&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer #GPCR #Pharmacology #DrugDiscovery #ScientificLeadership #DrGPCR Previous Next Recent Articles

Home → Flash News → New strategic partnership alert! 🚀 Dr.GPCR x Celtarys are teaming up to revolutionize fluorescent ligand development for GPCR research. Get custom, fast, and functional ligands backed by real scientists solving real assay problems. 🧪 “We don’t just deliver compounds. We solve assay problems.” – Dr. Maria Majellaro, CSO, Celtarys Listen to Ep. 168 now and meet your new assay partner 😉 ✳️ https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-168-with-dr.-maria-majellaro-from-celtarys #GPCRdrugDiscovery #FluorescentLigands #DrGPCR #BiotechTools #AssayDevelopment Published on June 10, 2025 Category Dr. GPCR Podcast New strategic partnership alert! 🚀 Dr.GPCR x Celtarys are teaming up to revolutionize fluorescent ligand development for GPCR research. Get custom, fast, and functional ligands backed by real scientists solving real assay problems. 🧪 “We don’t just deliver compounds. We solve assay problems.” – Dr. Maria Majellaro, CSO, Celtarys Listen to Ep. 168 now and meet your new assay partner 😉 ✳️ https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-168-with-dr.-maria-majellaro-from-celtarys #GPCRdrugDiscovery #FluorescentLigands #DrGPCR #BiotechTools #AssayDevelopment Previous Next Recent Articles

Home → Flash News → Think βCGRP is just αCGRP’s understudy? Think again. New research shows that βCGRP triggers distinct receptor signaling profiles across the CGRP receptor family, challenging the long-held assumption of redundancy. 🔬 A closer look reveals differences in G protein coupling, second messenger production, and receptor trafficking. 📊 This could reshape how we understand CGRP-related physiology—and how we target it in drug design. 🧠 Pain, inflammation, metabolism: the implications go far beyond signaling bias. 🔗 Read the full paper in Biochemistry: Unique Biased Agonism Profile of βCGRP on CGRP Family Receptors #GPCR #CGRP #DrugDiscovery #Pharmacology #SignalTransduction #Neuropeptides Published on June 16, 2025 Category GPCR Weekly News Think βCGRP is just αCGRP’s understudy? Think again. New research shows that βCGRP triggers distinct receptor signaling profiles across the CGRP receptor family, challenging the long-held assumption of redundancy. 🔬 A closer look reveals differences in G protein coupling, second messenger production, and receptor trafficking. 📊 This could reshape how we understand CGRP-related physiology—and how we target it in drug design. 🧠 Pain, inflammation, metabolism: the implications go far beyond signaling bias. 🔗 Read the full paper in Biochemistry : Unique Biased Agonism Profile of βCGRP on CGRP Family Receptors #GPCR #CGRP #DrugDiscovery #Pharmacology #SignalTransduction #Neuropeptides Previous Next Recent Articles

Home → Flash News → Did you know that A2B adenosine receptor-triggered calcium mobilization varies by cell type? A recent study explores how Gi, Gq, Gs proteins, and PKC contribute differently to intracellular Ca²⁺ signaling, revealing a more complex regulation than previously thought. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️https://www.ecosystem.drgpcr.com/receptor-activation-and-signaling/a2b-adenosine-receptor-triggered-intracellular-calcium-mobilization%3A-cell-type-dependent-involvement-of-gi%2C-gq%2C-gs-proteins-and-protein-kinase-c #gpcr #drgpcr #metabolism #obesity Published on March 10, 2025 Category GPCR Weekly News Did you know that A2B adenosine receptor-triggered calcium mobilization varies by cell type ? A recent study explores how Gi, Gq, Gs proteins, and PKC contribute differently to intracellular Ca²⁺ signaling, revealing a more complex regulation than previously thought. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️ https:// www.ecosystem.drgpcr.com/receptor-activation-and-signaling/a2b-adenosine-receptor-triggered-intracellular-calcium-mobilization%3A-cell-type-dependent-involvement-of-gi%2C-gq%2C-gs-proteins-and-protein-kinase-c #gpcr #drgpcr #metabolism #obesity Previous Next Recent Articles

< Back This is a Title 03 This is placeholder text. To change this content, double-click on the element and click Change Content. This is placeholder text. To change this content, double-click on the element and click Change Content. Want to view and manage all your collections? Click on the Content Manager button in the Add panel on the left. Here, you can make changes to your content, add new fields, create dynamic pages and more. You can create as many collections as you need. Your collection is already set up for you with fields and content. Add your own, or import content from a CSV file. Add fields for any type of content you want to display, such as rich text, images, videos and more. You can also collect and store information from your site visitors using input elements like custom forms and fields. Be sure to click Sync after making changes in a collection, so visitors can see your newest content on your live site. Preview your site to check that all your elements are displaying content from the right collection fields. Previous Next News Get in Touch Menu • Home • Services • About Menu • Home • Services • About Menu • Home • Services • About Menu • Home • Services • About Menu • Home • Services • About

<< Back to podcast list Strategic Partner(s) Dr. Kathryn E Livingston About Dr. Kathryn E Livingston Dr. Kathryn E Livingston is currently a Product Manager at Gator Bio , a biotechnology company providing solutions to researchers studying protein-protein interactions. Kathryn obtained her BS in Chemistry from Carnegie Mellon University and went on to receive a Ph.D. in Pharmacology at the University of Michigan. Working under the supervision of Dr. John Traynor , Kathryn worked to develop and understand first-in-class allosteric modulators of opioid receptors. Research into their mechanism of action in purified systems formed the base of her thesis work. Following this, Kathryn did a post-doctoral fellowship at UCSF in the laboratory of Dr. Mark von Zastrow . There she researched the beta-2 adrenergic receptor and developed assays to investigate real-time activity in intact cellular systems. Kathryn’s passion is developing solutions to problems in whatever form is most efficient: novel instrumentation, novel methods, or novel communication. Dr. Kathryn E Livingston on the web LinkedIn ResearchGate Pubmed Google Scholar Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Kevin Pfleger About this episode Dr. Pfleger trained as a pharmacologist and obtained his Ph.D. at the University of Edinburgh. I sat down with Kevin to chat about GPCRs, pharmacology, and his contributions to the field in both the academic and biotech worlds. Professor Pfleger has developed extensive expertise in profiling receptor binding and function at the molecular and cellular levels over the last 20 years, particularly involving GPCRs. He also has globally-recognized expertise in bioluminescence resonance energy transfer (BRET) technology, including his patented Receptor-Heteromer Investigation Technology (Receptor-HIT) for studying heteromers. Kevin is also Director, Biomedical Innovation at The University of Western Australia (UWA) and the MTPConnect Western Australian Life Sciences Innovation Hub. He is Head of Molecular Endocrinology and Pharmacology at the UWA Centre for Medical Research and Harry Perkins Institute of Medical Research, Deputy Director of the Australian Research Council Centre for Personalised Therapeutics Technologies, Chief Scientific Advisor to Dimerix, and co-founder of RAGE Biotech . He currently serves on the Board of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists and is a member of the British Pharmacological Society International Advisory Group. Join me and learn more about Kevin’s work and how he manages all his responsibilities. Dr. Kevin Pfleger on the web LinkedIn ResearchGate Pubmed Google Scholar University of Western Australia Harry Perkins Institute of Medical Research Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Gregory Tall About Dr. Gregory Tall " Dr. Gregory Tall earned his Ph.D. in Biomedical Sciences from U.T. Southwestern Medical Center with Bruce Horazdovsky, Ph.D. They worked on the interactome of yeast and mammalian Rab5 homologs including identification of Rab5 GEFs. In 2000, Dr. Tall moved upstairs to conduct his postdoctoral work on heterotrimeric G proteins and the novel interactor, Ric-8 with Alfred Gilman, M.D. Ph.D. In 2007, Dr. Tall joined the faculty in the Department of Pharmacology and Physiology at the University of Rochester Medical Center, there establishing his lab and major research directions. Dr. Tall moved to the University of Michigan in 2016 as an Associate Professor of Pharmacology and is a current active member of the department. The current goals of the Tall lab are to understand the basic mechanism by which Ric-8 proteins fold all heterotrimeric G protein alpha subunits, to exploit a Ric-8-based technology to purify recombinant G proteins and to use the G proteins in assays to explore the mechanisms of action of the 33-member adhesion GPCR family or Family B2 GPCRs. We found that adhesion GPCRs are activated by a tethered peptide agonist mechanism that differed from the common example known at the time, protease activated receptors (PARs). PARs have an N-terminal leader sequence that is clipped by exogenous proteases to reveal a new N-terminus that serves as the tethered agonist. Adhesion GPCRs pre-cleave themselves and the two resultant fragments of the receptor remain together to conceal the tethered peptide agonist. Mechanical dissociation of the two fragments aided by protein binding ligands and cell movement serves to decrypt the tethered agonist for binding to its orthosteric site. Our current goals are to explore this mechanism in detail and to understand how it may happen for the 33 adhesion GPCRs in complex physiological contexts…one being our discovery that GPR56 is the platelet receptor that senses collagen and shear force to initiate the platelet activation program. Dr. Tall has been continuously funded by the NIH since receiving an early RO1 award at Rochester. He has continued funding at Michigan through the MIRA R35 program. Dr. Tall has presented his work at 59 invited seminars including national and international meetings and academic departmental seminars. " Dr. Gregory Tall on the web The Tall Lab University of Michigan Google Scholar Twitter Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

AI is transforming GPCR modeling. Jens Carlsson challenges scientists to go beyond explaining data — and start predicting the future of receptor function and drug discovery. Home → Flash News → ep 175 with jens carlsson clip 3 AI is changing how we think about structure, function, and discovery Published on November 4, 2025 Category Dr. GPCR Podcast AI is changing how we think about structure, function, and discovery — but Jens Carlsson reminds us: the real test isn’t whether we can explain today’s data, it’s whether we can predict tomorrow’s results . In this clip, Jens unpacks a mindset shift that every computational scientist should hear. For decades, molecular modeling focused on explaining — rationalizing why a ligand binds, why a mutation shifts signaling, why a simulation behaves a certain way. But explaining is retrospective. Prediction is transformative. With tools like AlphaFold , his lab can now model receptor–peptide complexes in seconds — an achievement that once took months. Yet Jens’s caution stands: prediction must be proven. A good model doesn’t just match published structures; it forecasts new biology, new ligands, and new function. That’s where the future of GPCR research lies — not in describing the past, but in anticipating it. Whether you’re running simulations, screening compounds, or designing next-gen molecules, this insight reframes what “success” in computational pharmacology really means. 👉 Watch the full episode: model predict discover #GPCR #DrGPCR Previous Next Recent Articles

<< Back to podcast list Strategic Partner(s) Dr. Ross Cheloha About this episode Dr. Ross Cheloha is an Investigator at the National Institutes of Health in the Laboratory of Bioorganic Chemistry in Bethesda, MD, where he started in October 2020. He completed his postdoctoral training at MIT and Harvard Med School in the lab of Hidde Ploegh , where he developed new applications of single-domain antibodies (nanobodies). He earned his Ph.D. in Chemistry at the University of Wisconsin-Madison in the lab of Sam Gellman on the study of analogs of the GPCR peptide ligand parathyroid hormone. Work in his independent laboratory is focused on developing new pharmacological tools via chemistry and protein engineering to interrogate GPCR signaling. Ross and I chatted about his work and transition to an independent investigator; join me to learn more about class B GPCRs and Dr. Cheloha’s work. Dr. Ross Cheloha on the web NIDDK Cheloha Lab Google Scholar LinkedIn Twitter ResearchGate Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Home → Flash News → Can we preserve opioid pain relief without the side effects? 🔬 On Ep.166 of the Dr.GPCR Podcast, Ben Clements shares how positive allosteric modulators (PAMs) at the mu-opioid receptor could revolutionize treatment —with a 10x boost in methadone efficacy. Tune in for a masterclass on translational pharmacology, curiosity-driven science, and meaningful mentorship. 🎧 Full episode: Ep 166 with Dr. Ben Clements #GPCRresearch #DrGPCR #GPCRpodcast #OpioidPharmacology #DrugDiscovery Published on May 15, 2025 Category Dr. GPCR Podcast Can we preserve opioid pain relief without the side effects? 🔬 On Ep.166 of the Dr.GPCR Podcast, Ben Clements shares how positive allosteric modulators (PAMs) at the mu-opioid receptor could revolutionize treatment —with a 10x boost in methadone efficacy. Tune in for a masterclass on translational pharmacology, curiosity-driven science, and meaningful mentorship. 🎧 Full episode: Ep 166 with Dr. Ben Clements #GPCRresearch #DrGPCR #GPCRpodcast #OpioidPharmacology #DrugDiscovery Previous Next Recent Articles

<< Back to podcast list Strategic Partner(s) Dr. Randy Hall About Dr. Randy Hall Randy Hall, Ph.D., is a Professor of Pharmacology and Chemical Biology in the Emory University School of Medicine. Randy received his Bachelor's degree in 1990 from the University of New Hampshire and attended graduate school at the University of California at Irvine, studying the regulation of ionotropic glutamate receptors under the direction of Gary Lynch. After obtaining his Ph.D. in 1994, Randy moved to the Vollum Institute in Portland, Oregon, to do a post-doctoral fellowship in the laboratory of Thomas Soderling studying glutamate receptor trafficking and phosphorylation. In 1996, Randy continued his post-doctoral training at Duke University, where he studied the regulation of adrenergic receptors in the laboratory of Nobel Laureate Robert Lefkowitz . Randy then joined the faculty at the Emory University School of Medicine in 1999. Over the past two decades, his lab has published numerous groundbreaking findings shedding light on the signaling and regulation of GPCRs from the adrenergic, purinergic, glutamatergic, GABAergic, and adhesion sub-families. Most recently, his lab has made a number of seminal contributions to understanding the signaling, regulation and in vivo actions of the neuroprotective receptors GPR37 & GPR37L1 as well as the adhesion GPCRs BAI1, BAI2, and GPR56. Randy’s lab has a special interest in studying disease-associated mutations to human GPCRs that perturb receptor signaling and/or trafficking. Randy has received a number of research prizes, including the PhRMA New Investigator Award, the Distinguished Young Scholar in Medical Research Award from the W.M. Keck Foundation, and the John J. Abel Award from ASPET . In 2014, he was named a Fellow of the AAAS. In 2021, he co-authored the critically-acclaimed memoir of his mentor Bob Lefkowitz, entitled “A Funny Thing Happened on the Way to Stockholm: The Adrenaline-Fueled Adventures of an Accidental Scientist”. Join me to learn more about Randy’s work, hear his insights on the GPCR field, and also hear the story of how he came to co-author the memoir of his legendary mentor. Dr. Randy Hall on the web Hall Lab LinkedIn Google Scholar ResearchGate Dr. Lefkowitz Memoir. Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Patrick Sexton About Dr. Patrick Sexton Patrick Sexton is a Professor of Pharmacology, National Health and Medical Research Council of Australia Senior Principal Research Fellow, and Director of the Australian Research Council Centre for Cryo-electron Microscopy of Membrane Proteins ( www.ccemmp.org ). He is a leader in the study of GPCRs, biased agonism, and also on allosteric interactions between GPCRs and other proteins and small molecule ligands. More recently, his team has been at the forefront of the application of cryo-EM to elucidate of the structure and dynamics of GPCRs. Prof. Sexton has published over 320 peer-reviewed journal articles and has been cited >26,000 times (Google Scholar). He is a 2021 Clarivate Analytics Highly Cited Researcher in two disciplines: Pharmacology & Toxicology and Biology & Biochemistry, a corresponding member of the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification, and a member of the Faculty of 1000 (Molecular Pharmacology division) and an elected Fellow of the British Pharmacological Society (BPS). Prof. Sexton’s awards include the Australasian Society for Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Lecturer award, Endocrine Society of Australia Senior Plenary award, Rand Medal (ASCEPT), Paxinos-Watson Award (Australian Neuroscience Society), Vane Medal (BPS), Gordon Hammes Lectureship Award (American Chemical Society) and the GSK Research Excellence award. Prof. Sexton is also a co-founder of the San Francisco-based biotechnology company Septerna Inc . Dr. Patrick Sexton on the web CCeMMP Monash University Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Targeting adenosine signaling for immuno-oncology Date & Time Friday, November 3rd / 4:35 PM Abstract "Adenosine (ADO) signaling through A2A and A2B G protein-coupled receptors is increasingly recognized as an important immune checkpoint in the generation of anti-tumor immunity. Potent inhibitors of ADO signaling are currently being tested in cancer patients, including in randomized Phase 3 trial. I will present our recent work on adenosine-producing ectonucleotidases and adenosine signaling and discuss unexpected links between the adenosinergic pathway, DNA damage response and metabolic regulation." Authors and Affiliations John Stagg , David Allard . Centre de Recherche du Centre Hospitalier de l'Université de Montréal; Faculté de Pharmacie. 900 St-Denis, Montréal, QC, H2X 0A9. About John Stagg "John Stagg is a Professor of Pharmacy at Université de Montréal and researcher at the CHUM Research Centre. Distinguished immunologist, Dr Stagg is recognized for having identified the adenosine-producing enzyme CD73 as a new cancer target, and for his translational work in immuno-oncology. Dr Stagg has served as an expert consultant in the development of adenosine-targeting drugs, several of which now in clinical trials. Dr Stagg is a member of the Board of Directors of BioCanRx, Canada's Immunotherapy Network, co-founder and permanent member of the Scientific Advisory Board (SAB) of Surface Oncology, a clinical stage company developing next generation immunotherapies, and member of the SAB of Domain Therapeutics, a biopharmaceutical company focused on GPCR in immuno-oncology." John Stagg on the web University of Montréal Québec Cancer Consortium The University of Montreal Hospital Research Centre Pubmed LinkedIn Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

<< Back to podcast list Strategic Partner(s) Lauren Celano About this episode In this special Dr. GPCR podcast episode, we sat down to chat with Lauren Celano to talk about career options for Ph.D.’s. Working in a lab allows scientists to gain amazing hard and soft skills, which opens the doors to several great careers that many have not even considered, yet. Lauren has a science background and is passionate about helping talented scientists find their dream position. She is also a speaker, connector, recruiter, and coach. Lauren Celano on the web LinkedIn Propel Careers Email: Lauren@propelcareers.com Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Fiona Marshall About this episode Fiona Marshall got fascinated with GPCRs after attending a lecture on how the beta-adrenergic receptor in the heart is activated by adrenaline, during her undergraduate studies at Bath University. She then pursued her Ph.D. in neuroscience at Cambridge University. An expert in GPCR biology, Fiona published the first description of the cloning and structural requirements of the GABAB receptor. One of her career path-defining moments came when she visited Dr. Chris Tate and Dr. Richard Henderson at the Laboratory of Molecular Biology in Cambridge, UK. As a co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery and development biotechnology company, Fiona and her team made considerable breakthroughs in the field of GPCR stabilization and structure-based drug design. Today, Dr. Marshall is the VP Head of Neuroscience Discovery and Head of Discovery UK, Global Head of Neuroscience discovery research leading teams in West Point, Boston, and London at MSD. Join me and learn more about her fascinating career trajectory. Dr. Fiona Marshall on the web LinkedIn Twitter Google Scholar MSD UK Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Home → Flash News → GPCR activation is well-known to be a multi-step process. However, current molecular structures only capture the fully activated complex. Check out this paper to see how scientists combine different techniques to elucidate the intermediate GPCR-mini-Gαsβγ complex at 2.6 Å. Did you know that we work hard to bring you the most recent GPCR News, weekly? Catch up today in the Ecosystem using your free site membership! ➡️https://www.ecosystem.drgpcr.com/structural-and-molecular-insights-into-gpcr-function/structure-and-function-of-a-near-fully-activated-intermediate-gpcr-g%CE%B1%CE%B2%CE%B3-complex #gpcr #drgpcr Published on February 11, 2025 Category GPCR Weekly News GPCR activation is well-known to be a multi-step process. However, current molecular structures only capture the fully activated complex. Check out this paper to see how scientists combine different techniques to elucidate the intermediate GPCR-mini-Gαsβγ complex at 2.6 Å. Did you know that we work hard to bring you the most recent GPCR News, weekly? Catch up today in the Ecosystem using your free site membership! ➡️ https:// www.ecosystem.drgpcr.com/structural-and-molecular-insights-into-gpcr-function/structure-and-function-of-a-near-fully-activated-intermediate-gpcr-g%CE%B1%CE%B2%CE%B3-complex #gpcr #drgpcr Previous Next Recent Articles

Michelle Halls reminds us of something every scientist eventually learns: hard work is essential, but noticing the unexpected often defines your biggest breakthroughs. Home → Flash News → Scientific careers are not just built on brilliance Scientific careers aren’t just built on brilliance Published on November 14, 2025 Category Dr.GPCR Podcast Scientific careers aren’t just built on brilliance—they’re shaped by curiosity, timing, and paying close attention. In this conversation, Michelle Halls reminds us of something every scientist eventually learns: hard work is essential, but noticing the unexpected often defines your biggest breakthroughs. She also names a truth we rarely acknowledge out loud—luck and timing matter. Many talented scientists leave the field not because they lacked skill, but because the right opportunity didn’t land at the right time. And that’s why attention to detail, persistence, and a bit of serendipity can change the trajectory of a research career. 🎧 Watch this moment — then catch the full episode: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/leadership-luck-and-gpcr-signaling #GPCR #DrGPCR Previous Next Recent Articles

Home → Flash News → Behind every great discovery is a great question 🚀 Dr. Dmitry Veprintsev shares how asking the right GPCR questions and dreaming big have shaped his work, in the latest Dr. GPCR podcast episode. If you’re passionate about GPCRs and drug discovery, this episode is a must-listen! ✳️Listen at Ep 163 with Dr. Dmitry Veprintsev #DrGPCR #GPCRPodcast #Biotech #Pharmacology #GPCRScience Published on April 10, 2025 Category Dr. GPCR Podcast Behind every great discovery is a great question 🚀 Dr. Dmitry Veprintsev shares how asking the right GPCR questions and dreaming big have shaped his work, in the latest Dr. GPCR podcast episode. If you’re passionate about GPCRs and drug discovery, this episode is a must-listen! ✳️Listen at Ep 163 with Dr. Dmitry Veprintsev #DrGPCR #GPCRPodcast #Biotech #Pharmacology #GPCRScience Previous Next Recent Articles

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Complimentary Lunch < Previous Session Next Session >

<< Back to podcast list Strategic Partner(s) Dr. Antonella Di Pizio About this episode In this episode of the Dr. GPCR podcast , we meet with Dr. Antonella Di Pizio, an independent research group leader at the Leibniz Institute for Food Systems Biology at the Technical University of Munich. Antonella trained as a medicinal chemist in Italy, followed by a Ph.D. in computational medicinal chemistry, during which she developed a taste for structural biology. Antonella then moved to Israel, where she first started working on bitter taste GPCRs in Dr. Masha Niv's lab . Today, Antonella has expanded her research to olfactory GPCRs and trace amine receptors. Join us to learn more about chemosensory GPCRs and how computational pharmacology can help better understand their function. Dr. Antonella Di Pizio on the web Leibniz-Institute for Food Systems Biology at the Technical University of Munich Google Scholar PubMed LinkedIn Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Home → Flash News → In case you haven’t heard, registrations are open for the next 4-week course “Development of GPCR Ligands as Therapeutic Drugs,” with Dr. Terry Kenakin 👏 Spots are filling up fast, run and save yours, and enjoy a 25% discount with your Premium Membership 🚀 ✳️Go to https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs #gpcr #drgpcr Published on February 22, 2025 Category Dr. GPCR Courses In case you haven’t heard, registrations are open for the next 4-week course “Development of GPCR Ligands as Therapeutic Drugs,” with Dr. Terry Kenakin 👏 Spots are filling up fast, run and save yours, and enjoy a 25% discount with your Premium Membership 🚀 ✳️Go to https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs #gpcr #drgpcr Previous Next Recent Articles

Join the forefront of GPCR research at the Dr. GPCR Summit! Embracing innovation and technology, we connect global scientific communities. Experience talks spanning time zones, with options for live or pre-recorded presentations. Uncover groundbreaking insights in GPCR science together. GPCR EVENT Dr. GPCR Summit 2022 Dr. GPCR Ecosystem Partners Welcome to the official page of the 3rd edition of the Dr. GPCR Summit This year the Summit will be held between October 10th and 16th. You can join us for free when you become a Dr. GPCR Ecosystem site member, which is also free! The content of the Summit will only be available to site-members who must be approved to join us. You can participate: As an attendee by becoming a site member. It only takes a minute, and it's free With your pre-recorded talk By presenting a poster on Wonder By giving a live talk. Space is limited, and we will do our best to accommodate your request For Speakers and presenters: Make sure you are registered as a site member to get access to the entire Summit for Free! Verify that you talk data and time are in your calendar. You can verify it too by checking out the schedule on our website. Live talks should be 30 mins with 15 mins Q/A. Live trainee talks should be 15 mins with 5 mins Q/A. All live talks will be on Zoom, the link will be added to your calendar invite and will be available here on our website but only visible to registered site-members. Similar to previous years: The meeting will be virtual (on Zoom) to host as many participants as possible Live talks will be hosted on Zoom from October 10th to the 14th Trainees are invited to participate by presenting a trainee talk, a poster, or a pre-recorded talk Presentation prizes will be available for the best trainee talks and posters We are also trying out a few new things: Networking and poster sessions on Wonder A full day dedicated to trainee talks Workshops and panel discussions In case you'd like to present your work, you'll need: Become an Ecosystem site member Pick the correct form and submit it before September 30th, 2022 You'll need a 1-minute video abstract in addition to the written version You can always email us with any questions and comments at Hello@DrGPCR.com << Submit your live talk details >> << Submit a pre-recorded talk >> << Submit your poster >> << Live talk schedule >> << Pre-recorded talk list >> << Poster presentation list >> Tags Dr. GPCR Summit Dr. GPCR Summit 2022 Dr. GPCR Summit 2022 Schedule Dr. GPCR Summit 2022 Details Dr. GPCR Summit 2022 Pre-Recorded Talks Dr. GPCR Summit 2022 Live Talks Dr. GPCR Summit 2022 Poster Presentations Submit Pre-Recorded Talk Presentation for Dr. GPCR Summit 2022 Submit Live Talk Presentation for Dr. GPCR Summit 2022 Submit Poster Presentation for Dr. GPCR Summit 2022

Showcase your creativity in the AGPCR24 Logo Contest! Submit your design to represent the Adhesion GPCR Workshop and inspire our global community. LOGO CONTEST Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Register Rules for the logo contest Design must be based on “Alebrijes” [ah-leh-bree-hez], which are chimeric creatures from Mexican folklore AND contain adhesion GPCRs Avoid copyrighted material unless a CC BY / open-use license has been acquired or generated (Adobe Stock, etc). The Consortium must be free to use the design. Requirements: Resolution 300 ppi max, JPEG/TIFF/EPS/PNG/PDF formats, 5MB max Open to all adhesion GPCR community members. Artist-scientists must be registered to attend the adhesion GPCR workshop 2024 in Mexico City. The contest deadline is August 15th, 2024, 11:59 PM CST (designs received after the deadline will not be considered) Designs or inquiries should be sent to this email The prize for the selected design will include free registration and more! Register for the Adhesion GPCR 2024 Learn more about the Adhesion GPCR workshop 2024 Up About the event Learn more about the Adhesion GPCR workshop 2024 and its preliminary program. Up About the venue Discover Cinvestav, the host venue for the upcoming workshop. Up Abstract Submission Submit your research abstracts following our guidelines to present at the conference. Up Traveling Tips Find essential tips about Mexico City, including transportation options and local insights.

Need help? Submit a problem! Get detailed information about incidents and find solutions. Join us today! Report an Incident Thank you for taking the time to report any incidents or issues you are experiencing with our site. Your comments will help us improve and refine the Ecosystem. Who is submitting this incident? First Name Last Name Email Details about this incident Please describe your concern Link to the page where you experienced difficulties Please feel free to upload screen shots or short videos of your concern. Upload File Upload supported file (Max 15MB) Submit Thanks for submitting!

Home → Flash News → Terry's Corner is Officially LIVE! 🎉 This is your new go-to for mastering drug discovery pharmacology. No fluff, just clear, on-demand insights from Terry Kenakin. Building core expertise? Master dose-response, binding, kinetics, and foundational models. Driving drug discovery? Apply pharmacology to selectivity, ADME, and strategic decision-making. An experienced drug hunter? Sharpen your edge with allosteric bias, residence time, and translational PK/PD. Learn on-demand, apply immediately: https://terrykenakin.com #DrGPCR #GPCR #pharmacology #TerrysCorner #DrugDiscovery Published on July 2, 2025 Category Terry's Corner Terry's Corner is Officially LIVE! 🎉 This is your new go-to for mastering drug discovery pharmacology. No fluff, just clear, on-demand insights from Terry Kenakin. Building core expertise? Master dose-response, binding, kinetics, and foundational models. Driving drug discovery? Apply pharmacology to selectivity, ADME, and strategic decision-making. An experienced drug hunter? Sharpen your edge with allosteric bias, residence time, and translational PK/PD. Learn on-demand, apply immediately: https://terrykenakin.com #DrGPCR #GPCR #pharmacology #TerrysCorner #DrugDiscovery Previous Next Recent Articles

Join Dr. GPCR and become an Ecosystem Contributor! Discover how you can make a positive impact on the field and inspire others to do the same. Ecosystem Contributor - Coming Soon -

Discover the mission, vision, and people behind the Dr. GPCR Ecosystem: uniting scientists, biotech, and innovators to advance GPCR research worldwide. Who We Are We are a global network of scientists, biotech innovators, pharma professionals, CRO leaders, and vendors—united by one mission: to make working on GPCRs easier, faster, and more collaborative. Dr. GPCR is both expert-led and community-first. We’re building together, with input from across the field. About Dr. GPCR Ecosystem We unite the GPCR Community to advance drug discovery Where GPCR Experts Move Science Forward Join the global community accelerating GPCR drug discovery through trusted insights, expert tools, and powerful connections. Join Free & Get Our Weekly News See Why it Matters 6,600+ followers 200+ Research Labs 1,500+ Scientists 50+ Biotech Companies Built by Scientists. Driven by Impact. Dr. GPCR began as a podcast. Now, it's a global ecosystem of scientists, biotech teams, CRO leaders, and trainees working to move GPCR science forward—together. We created this space to make trusted knowledge and collaborations easier to access—without noise, fluff, or hype. What We Believe The Ecosystem was built with five key beliefs: Scientific rigor first This is a space for data-driven work, not hype. Usefulness over flash Every piece of content and feature must be practical. Transparency builds trust We're open about who we are and what we do. Collaboration is key Progress in GPCR science requires a collective effort. Inclusion matters We welcome diverse voices, experiences, and expertise. We designed the Ecosystem to support your work —no matter where you are in your GPCR journey. Our Journey (So Far) From the first podcast episode to a global platform, it's all built by and for the GPCR community. 2020 First Podcast Episode Launched our podcast to share expert insights with the scientific community. 2021 2nd Annual Summit Increased our reach and impact with the GPCR Community 2022 Community Platform Expanded beyond content to create a dedicated space for GPCR scientists to connect. 2023 First Symposium Inaugural Dr. GPCR Symposium with over 100 attendees 2024 GPCR University Launched comprehensive courses and expert talks to deepen scientific understanding. 2025 Terry's Corner & Consulting Launched our exclusive program with Dr. Kenakin and offered to CROs consulting services See Full Timeline The Field Is Growing—but Fragmented As GPCR scientists, we know the problem: too much noise, too little time, and nowhere to connect that's built for us. We built Dr. GPCR to: Curate relevant data—not overwhelm you with it Connect researchers with CROs, peers, and biotech leaders Provide high-quality tools and expert insights on demand Whether you're in a lab, launching a startup, or prepping for due diligence, we built this for you. The GPCR Challenge Scientists waste an average of 12 hours per week searching for relevant GPCR research and connections. Our ecosystem cuts that time by 80%. You'll Be in Good Company From PhDs to CRO execs to rising biotech founders—this is a vetted, mission-aligned community built to help you move faster. Premium Members Include: ✔ Drug hunters at early-stage biotechs ✔ CRO leaders building assays and tools ✔ Academic researchers moving into translational work ✔ Teams preparing for fundraising or due diligence Expert Contributors Include: ✔ Terry Kenakin, with his exclusive series on GPCR pharmacology ✔ Sam Hoare, simplifying GPCR data analysis ✔ Global CROs and biotech leaders, contributing behind-the-scenes tools and insight What Makes the Ecosystem Different Built for Drug Discovery Designed by scientists in the GPCR space to accelerate your research goals Collaborative by Design Connects researchers, CROs, and biotech teams—not just profiles, real relationships. Results-Driven Every tool and content block is built to help you make a decision or move forward. ✔ GPCR-specific content ✔ Expert curation ✔ Vetted community What Joining the Ecosystem Looks Like 1 Join Free Sign up in seconds. You'll instantly receive the GPCR Weekly News (free version). 2 Get Verified We manually review each profile to ensure trust and scientific relevance. 3 Start Exploring Browse free content, community updates, and learn what's available. 4 Upgrade Anytime Premium unlocks exclusive courses, community features, and deeper insights. Start Your Journey Today Meet the Leadership Founder & Director Yamina Berchiche Get in Touch Board Member Anne M. Quinn Get in Touch Board Member Maria Waldhoer Get in Touch Co-Founder Attila Foris Get in Touch Board Member JoAnn Trejo Get in Touch Chief Matchmaker Mark Schmeizl Get in Touch Why Upgrade to Premium Everyone who joins receives the free Weekly News. Premium gives you everything else—the full toolbox for moving science forward. Free Membership Includes: ✔ Free version of GPCR Weekly News - straight to your inbox! ✔ Select news and content ✔ Ecosystem and podcast updates Premium Members Unlock: ✔ Full Weekly News access – All GPCR papers, events, jobs + expert commentary ✔ Dr. GPCR University – 5 on-demand GPCR courses, 1 project management course, 200+ expert talks ✔ Community tools – Member directories, messaging, and forums Partners Who Drive our Mission Partner Benefits Visibility to GPCR experts Direct connections Industry insights Explore Partnership Opportunities Ready to Join the Movement? Start free. Upgrade when you're ready. Dr. GPCR helps you stay ahead of the curve in science and strategy. Unlock Premium Access Join Free Now